Study Summary
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
Want to learn more about this trial?
Request More InfoInterventions
CLBR001 and SWI019COMBINATION_PRODUCT
No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | United States |
| University of California at San Diego | San Diego | California | United States |
| University of Chicago | Chicago | Illinois | United States |
| Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota | United States |
| Weill Cornell Medical College - New York Presbyterian Hospital | New York | New York | United States |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | United States |
| Sarah Cannon Research Institute - Tennessee Oncology | Nashville | Tennessee | United States |
| Sarah Cannon Research Institute - Texas Transplant Institute | San Antonio | Texas | United States |